Kerecis logo — Kerecis is pioneering the use of fish skin and fatty-acids i...

Kerecis

Kerecis is pioneering the use of fish skin and fatty-acids in the cellular therapy and regenerative medicine market.

Founded 2011 Iceland Iceland 517 employees Debt Financing Total: $210.77M Health Care, Manufacturing +1

General Information

Company Name Kerecis
Founded Year 2011
Location Iceland Iceland
Founders / Decision Makers
Team member Team member Team member Team member Team member Team member
Employees 517
Industries Health Care, Manufacturing, Medical Devices
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Kerecis. To contact Kerecis, visit kerecis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kerecis compare?

A PDF of Kerecis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kerecis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kerecis

Kerecis is a pioneering company in the cellular therapy and regenerative medicine market, using fish skin and fatty acids to revolutionize tissue healing. Founded in 2009 by Fertram Sigurjonsson, the company's patented technologies leverage fatty-acid rich products to enable tissue regeneration, minimizing scarring. Their products are utilized in treating trauma, chronic wounds, burns, and diabetic wounds, with future applications in oral surgery, plastic surgery, and neurological treatments. Kerecis is driven by a vision to extend human life by supporting the body’s own regenerative abilities and a mission to lead the world in regenerative medicine while sustainably harnessing nature’s remedies. A significant milestone for Kerecis was reached in August 2023 when it achieved unicorn status, becoming Iceland’s first unicorn with a groundbreaking acquisition by the Danish company Coloplast for an impressive $1.3 Billion. This achievement solidifies the company's position as a leader in the industry. In its most recent funding round, Kerecis secured a $60.00M Series D investment on 21 July 2022, with notable investors including Emerson Collective, KIRKBI, Brú Pension Fund, and LSV. Kerecis has carved out a unique position in the Health Care and Manufacturing sectors, driving innovation from its headquarters in Iceland. With its groundbreaking technology and strong investor backing, Kerecis is poised to continue its trajectory of success and influence in the regenerative medicine market.

Business keywords: Regenerative Medicine, Cellular Therapy, Wound Care, Burn Treatment, Surgical Procedures, Dental Applications, Omega-3, Fish-skin Technology, Tissue Regeneration, Startup, Investment, Healthcare Innovation, Biomedical Research

Funding Rounds & Investors (19)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $15.00M 1
Silicon Valley Bank
21 Jul 2022
Series D $60.00M 4
Emerson Collective, KIRKBI +2
21 Jul 2022
Convertible Note $6.00M 1
Silicon Valley Bank
27 Aug 2020
Series C $16.00M 4
Emerson Collective, Novator +2
13 Jun 2019
Convertible Note $3.00M -
07 Jan 2018
Grant Undisclosed -
01 Jun 2017
Series B $3.00M -
13 Jul 2016
Grant ISK15.00M 1
Technology Development Fund
01 Mar 2016
Grant $370.00K 1
Technology Development Fund
15 Dec 2015
Grant ISK30.00M 1
Technology Development Fund
01 Mar 2015

View All 19 Funding Rounds

Kerecis Alternatives & Competitors

View All Alternatives
Kerecis vs
SANUWAVE
SANUWAVE United States

Heal Wounds With Energy First

Post-IPO Equity
54 employees
Biotechnology, Health Care
Kerecis vs

Developing and commercializing advanced extracellular matrix devices for effective tissue and organ...

Venture round
1001-5000 employees
Health Care, Manufacturing
Kerecis vs

From replacement to regeneration

11 employees
Biotechnology, Health Care

FAQ About Kerecis

Kerecis is pioneering the use of fish skin and fatty-acids in the cellular therapy and regenerative medicine market.
Kerecis was founded in 2011.
Kerecis is headquartered in Iceland.
Kerecis operates in Health Care, Manufacturing and Medical Devices. Its work centres on Regenerative Medicine, Cellular Therapy, Wound Care and Burn Treatment.
Kerecis has approximately 517 employees.
Kerecis has completed 19 funding rounds, raising a total of $210.77M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Kerecis include SANUWAVE, ACell, osteobionix, Regenesis, CoNextions Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kerecis and SANUWAVE are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kerecis, https://bouncewatch.com/company/kerecis, updated 25 March 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes